Plasma levels of mannan‐binding lectin‐associated serine proteases MASP‐1 and MASP‐2 are elevated in type 1 diabetes and correlate with glycaemic control. (May 2015)

• Record Type: Journal Article
• Authors: Jenny, L.; Ajjan, R.; King, R.; Thiel, S.; Schroeder, V.
• Is Part Of: Clinical and experimental immunology. Volume 180:Number 2(2015:May)
• Page Start: 227
• Page End: 232
• Publication Date: 2015-05
• Subjects: Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12574
• Languages: English
• ISSNs: 0009-9104

Abstract

<abstract abstract-type="main"> <title>Summary</title> <p>There is increasing evidence that the complement system plays an important role in diabetes and the development of diabetic vascular complications. In particular, mannan‐binding lectin (MBL) levels are elevated in diabetes patients, and diabetes patients with diabetic nephropathy have higher MBL levels than diabetes patients with normal renal function. The MBL‐associated serine proteases (MASPs) MASP‐1, MASP‐2 and MASP‐3 and MBL‐associated protein MAp44 have not yet been studied in diabetes patients. We therefore measured plasma levels of MASP‐1, MASP‐2, MASP‐3 and MAp44 in 30 children with type 1 diabetes mellitus (T1DM) and 17 matched control subjects, and in 45 adults with T1DM and 31 matched control subjects. MASP‐1 and MASP‐2 levels were significantly higher in children and adults with T1DM than in their respective control groups, whereas MASP‐3 and MAp44 levels did not differ between patients and controls. MASP‐1 and MASP‐2 levels correlated with HbA1c, and MASP levels decreased when glycaemic control improved. Because MASP‐1 and MASP‐2 have been shown to interact directly with blood coagulation, elevated levels of these proteins may play a role in the enhanced thrombotic environment and consequent vascular complications in diabetes.</p> </abstract>